2019
DOI: 10.1111/aji.13097
|View full text |Cite
|
Sign up to set email alerts
|

Tacrolimus treatment for infertility related to maternal‐fetal immune interactions

Abstract: Many approaches have been used to achieve successful pregnancies in patients with infertility, though existing treatments remain unsatisfactory in patients with infertility caused by abnormal maternal-fetal immunity. However, our understanding of the immunological aspects of infertility has steadily progressed, aided by recent research into organ transplantation and cancer. The results of these recent analyses have led to the development and evaluation of several candidate immunological treatments, but the use… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 113 publications
(161 reference statements)
0
13
0
Order By: Relevance
“…Currently, use of the new immunosuppressive agents tacrolimus and cyclosporine, which minimize immune rejection of transplanted organs, has been proposed as useful for infertile patients with immune overactivation [148,149]. When infertile patients with overactive immune conditions were carefully selected, tacrolimus was reported to improve the pregnancy outcome [149][150][151]. To support this approach, a common mTOR (mammalian target of rapamycin) inhibitor, sirolimus, which effectively prevents allograft rejection, was recently demonstrated to improve clinical pregnancy and live birth rates after repeated IVF therapy failures by reducing the Th17/Treg cell ratio [152].…”
Section: Topics Of Clinical Application Of Immune Therapymentioning
confidence: 99%
“…Currently, use of the new immunosuppressive agents tacrolimus and cyclosporine, which minimize immune rejection of transplanted organs, has been proposed as useful for infertile patients with immune overactivation [148,149]. When infertile patients with overactive immune conditions were carefully selected, tacrolimus was reported to improve the pregnancy outcome [149][150][151]. To support this approach, a common mTOR (mammalian target of rapamycin) inhibitor, sirolimus, which effectively prevents allograft rejection, was recently demonstrated to improve clinical pregnancy and live birth rates after repeated IVF therapy failures by reducing the Th17/Treg cell ratio [152].…”
Section: Topics Of Clinical Application Of Immune Therapymentioning
confidence: 99%
“…When it comes to immunity and pregnancy, it is universally acknowledged that immune tolerance to the semi-allogeneic fetus is significantly rudimentary for a successful pregnancy. Abnormalities of endometrial immunity are involved in the pathogenesis of RIF ( 67 , 68 ). At present, research on the immune microenvironment in the endometrium of RIF during WOI is in full swing.…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, Th2 dominance is required for successful implantation and pregnancy. Recurrent implantation failure and pregnancy loss were negatively correlated with Th1 cell numbers [ 8 ]. In addition, NK cells increased in number at the decidua in a case of chromosome-normal abortion [ 9 ].…”
Section: Discussionmentioning
confidence: 99%